health-economic analysis regarding HPV-vaccination of boys

Documentación CAPI
Virus del papiloma humano
Título(s) original(es)
Komplettering av beslutsunderlag om HPV-vaccination av pojkar
Documento de antecedentes
NITAG Sweden
Año de publicación


The health economic analysis compared the health effects and costs of introducing sex-neutral HPV vaccination to a situation where only girls are vaccinated. The analysis used a time horizon of 100 years and took herd immunity into account. Costs included the direct costs for the vaccine and for resource use within the healthcare sector, and indirect costs in the form of productivity losses.
If girls are offered vaccination against HPV with a bi- or tetravalent vaccine, it would be cost-effective to also vaccinate boys with the same type of vaccine, even at the current list price (Incremental Cost Effectiveness Ratio, ICER, of 375 000 SEK). If girls are offered the nonavalent vaccine, the ICER would be about 615 000 SEK to also offer boys vaccination with this vaccine, given the current list price. If procurement led to a 35 percent lower price, the ICER using the nine-valent vaccine would be comparable to using the bi- or tetravalent vaccine, and be considered cost-effective.
In a situation where both girls and boys are already offered vaccination with a bi- or tetravalent vaccine, the ICER would be close to 1.5 million SEK (at list price) to offer them vaccination with a nonavalent vaccine instead. If the price difference between the two types of vaccines was to be decreased by approximately 30 percent, a switch from a bi-/tetravalent to a nonavalent vaccine could be considered cost-effective.
The yearly cost of a bi- or tetravalent vaccine for one cohort of boys at 80 percent vaccination coverage would be about 80 million SEK, at list price. If the price of the vaccine was about 85 percent lower than today’s list price, similar to the 2017 procurement price of the tetravalent vaccine Gardasil in Sweden, the introduction of sex-neutral vaccination would imply an increase in costs of about 12 million SEK annually. The corresponding figures for the nonavalent vaccine would be 135 million SEK at list price and 20 million SEK with an 85 percent rebate. Costs of administering the vaccinations to boys would amount to an additional 5‒11 million SEK annually according to prior estimations, and would be independent of the choice of vaccine. The costs for vaccinating girls are not included in these calculations.


Noticias y eventos relacionados

  • Alemania
    Documento de antecedentes

    the German NITAG publishes the background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine


    The STIKO recommends vaccination with the adjuvanted herpes zoster subunit (HZ/su) inactivated vaccine for the prevention of herpes zoster (HZ) and postherpetic neuralgia (PHN) for all people age 60 years and over (standard vaccination).

    Leer más
  • Suecia

    Changing national vaccination programmes in Sweden


    This report outlines how the Public Health Agency of Sweden organizes and investigates changes to national vaccination programmes. The main target group of the English version of the report is National Immunization Technical Advisory Groups (NITAGs) and their Secretariats in other countries.

    Leer más
  • Suecia

    A NITAG for Sweden


    The first meeting of the Swedish reference group in May 2016 marks the birth of the Swedish NITAG. Until 2015, Sweden was among the 11 countries that did not declare having a NITAG in the WHO-UNICEF Joint Reporting Form. This is no longer the case. Around the table, 12 experts, nominated by relevant Swedish institutions (Child Health Care Units, Medical Products Agency, The National Board of Health and Welfare, The Swedish Association of Local Authorities and Regions) and professional societies (Clinical Microbiology, Infectious Diseases, General Practice, Pediatrics, School nurses and doctors), and approved by the Public Health Agency, met for the first meeting of this brand new committee. 

    Leer más